The emergence of e-cigarettes on the consumer market led to a tremendous rise in e-cigarette consumption among adolescents in the United States. The success of JUUL and other pod systems was linked to its high nicotine delivery capacity. In compliance with the European Tobacco Product directive, liquid nicotine contents in the European JUUL variants are limited to 20 mg/mL or below. A short time after launching the initial version in Europe, JUUL pods have been modified in terms of the wick material used. This modification has been demonstrated previously to lead to an elevated aerosol generation, consequently, to a larger amount of nicotine per puff generated. The present study was designed to assess whether the mentioned differences between the "initial" and "modified" JUUL versions may cause a significant difference during consumption, and how nicotine delivery compares with tobacco cigarettes. In this single-center three-arm study, nicotine pharmacokinetics and influence on urge to smoke/vape were compared for tobacco cigarettes, the "initial" version of the European JUUL, and the "modified" version of the European JUUL. Participants, 15 active smokers and 17 active e-cigarette users, were instructed to consume their study product according to a pre-directed puffing protocol. Venous blood was sampled for nicotine analysis to cover the acute phase and the first 30 min after starting. Nicotine delivery and the reduction of urge to smoke/vape upon usage of both European JUUL variants were lower in comparison to tobacco cigarettes. This suggests a lower addictive potential. Modification of the pod design did not result in significant differences at the first ten puffs, as confirmed by a vaping machine experiment. Apparently, the limitations by the initially used wick material only come into effect after longer usage time.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187405 | PMC |
http://dx.doi.org/10.1038/s41598-021-91593-6 | DOI Listing |
Anal Chim Acta
January 2025
Interdisciplinary Nanoscience Center (iNANO), Faculty of Natural Sciences, Aarhus University, Gustav Wieds Vej 14, 8000, Aarhus C, Denmark. Electronic address:
Background: Existing liquid biopsy assays for protein biomarkers of cancer are mostly based on antibodies (Ab) contributing unfavorably to their high cost. Easy to express and modify in vitro, nanobodies may be a cost-effective alternative to Ab.
Results: We show that serum HER-2/neu, a biomarker and target of aggressive HER-2/neu(+) cancers, can be accurately detected in a 1.
Int J Hyg Environ Health
December 2024
Centre for Occupational and Environmental Health, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Background: We aimed to develop a method for assessing occupational styrene exposures for application in epidemiological studies on risks of lymphohematopoietic neoplasms and other malignant and non-malignant diseases in the European and the US glass reinforced plastics industries.
Method: We estimated a linear mixed effects model based on individual airborne personal measurements of styrene from the glass reinforced plastics industry in Denmark, Norway, Sweden, UK, and the US. The most suitable model was chosen based on its predictive power as assessed using cross validation with different combinations of predictors; and by comparing their prediction errors.
Eur J Pediatr
December 2024
Department of Child and Adolescent Psychiatry, Aarhus University Hospital Psychiatry, Palle Juul-Jensens Boulevard 175, 8200, Aarhus N, Denmark.
iScience
November 2024
Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
United European Gastroenterol J
December 2024
Department of Surgery, Maastricht University (Maastricht University, Including Maastricht UMC+), Maastricht, The Netherlands.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!